Abstract
Purpose: There remains an unmet medical need for radioprotective and mitigative agents. BP-C2 is a novel lignin-derived polyphenolic composition with ammonium molybdate, developed as radioprotector/radiomitigator. Objectives: The present study evaluated BP-C2 for the mitigation of acute radiation syndrome (ARS). Methods: A total-body irradiation mouse model (TBI, 4.0–8.0 Gy) was used in the study. Results: In a 30-day survival study, performed in CBA mice, BP-C2, at a dosage of 81.0 mg/kg, improved survival (dose reduction factor (DRF) = 1.1) and increased the formation of endogenous spleen colony-forming units (CFU). In C57BL/6 mice, BP-C2, when administered daily for 7 days, starting 24 hours after TBI, also improved survival. In animals irradiated with 5.0 Gy, BP-C2 increased the number of CFUs (6.7 ± 5.1) compared to the 5.0 Gy placebo group (2.3 ± 2.3, p =.0245). The number of surviving intestinal crypts was maintained in the 5.0 Gy BP-C2 group (133.7 ± 13.9), in contrast to the 5.0 Gy placebo group (124.2 ± 10.5, p
Author supplied keywords
Cite
CITATION STYLE
Bykov, V. N., Drachev, I. S., Kraev, S. Y., Maydin, M. A., Gubareva, E. A., Pigarev, S. E., … Panchenko, A. V. (2018). Radioprotective and radiomitigative effects of BP-C2, a novel lignin-derived polyphenolic composition with ammonium molybdate, in two mouse strains exposed to total body irradiation. International Journal of Radiation Biology, 94(2), 114–123. https://doi.org/10.1080/09553002.2018.1416204
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.